STOCKHOLM – May 26, 2025. Umecrine Cognition today announces that the company has informed its clinical partners and study center investigators that they may resume the inclusion of eligible…
STOCKHOLM – May 20, 2025. The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the annual general meeting at 14:00 (CEST) on Thursday 12 June 2025 at…
STOCKHOLM – May 7, 2025. Umecrine Cognition today announces that the company will present validation and implementation data for the newly developed clinical scale CGI-S-PBC™ (Clinical Global…
STOCKHOLM – May 5, 2025. Umecrine Cognition today announces that the company has been awarded a research grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The funding will…
STOCKHOLM – April 7, 2025. Umecrine Cognition today announces that the company will attend the high-level meeting International PBC Summit 2025 on April 8-11. The summit is organized by the…
STOCKHOLM – April 1, 2025. Umecrine Cognition today announces the appointment of Dr. Viktor Drvota as new Chief Executive Officer. He succeeds Anders Karlsson, who has served in the position since…
STOCKHOLM – April 1, 2025. Umecrine Cognition today announces that the company will attend the 19th International Conference on Alzheimer’s and Parkinson’s Diseases 2025 in Vienna,…
STOCKHOLM – March 18, 2025. Umecrine Cognition today announces that its Phase 1b/2a study of golexanolone has been delayed due to technical issues with the production of capsules used in the study….
STOCKHOLM – March 19, 2025. Umecrine Cognition today announces that the company will attend BIO-Europe Spring® in Milan, Italy. The meeting takes place March 17–19th and is expected to gather…
STOCKHOLM – January 13, 2024. Umecrine Cognition today announced that the company will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, USA, on January 13–16, 2025….